80 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective …
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
an accumulated deficit of approximately $97 million, see “—Liquidity and Capital Resources” below.
Although we provide no assurance, we believe that our
6-K
EX-99.2
ktag4v6kkmr97cwre
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
9v1nuv4lgs
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
nhg7c92drh0v mmh3
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
1ombolwe
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
e3pd3
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
vnsw0es40m s8f
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
u74ps7u2 50
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.2
wvwbo
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
ovdytn6xcp
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm